Genetically Encoded Cholesterol-Modified Polypeptides.
J Am Chem Soc · 2019
Last updated 2026-05-28Researchers created a new type of material by attaching cholesterol to a protein called exendin-4, which is used to treat type 2 diabetes. This cholesterol-modified version of the protein self-assembled into tiny structures called micelles and worked as effectively as standard treatments in activating a key receptor involved in blood sugar control.
AI summary of the abstract below.
| Journal | J Am Chem Soc, 2019 |
|---|---|
| Citations | 34 |
| Relative citation ratio | 1.51 |
| NIH percentile | 65 |
| Molecules | — |
Abstract
Biological systems use post-translational modifications (PTMs) to control the structure, location, and function of proteins after expression. Despite the ubiquity of PTMs in biology, their use to create genetically encoded recombinant biomaterials is limited. We have utilized a natural lipidation PTM (hedgehog-mediated cholesterol modification of proteins) to create a class of hybrid biomaterials called cholesterol-modified polypeptides (CHaMPs) that exhibit programmable self-assembly at the nanoscale. To demonstrate the biomedical utility of CHaMPs, we used this approach to append cholesterol to biologically active peptide exendin-4 that is an approved drug for the treatment of type II diabetes. The exendin-cholesterol conjugate self-assembled into micelles, and these micelles activate the glucagon-like peptide-1 receptor with a potency comparable to that of current gold standard treatments.
Verbatim abstract via PubMed 30608674 ↗